Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice

Steve T. Russell, Michael J. Tisdale

Research output: Contribution to journalArticle

Abstract

Zinc-alpha(2)-glycoprotein (ZAG) is an adipokine associated with fat loss in cancer cachexia. The purpose of this study was to evaluate the ability of recombinant human ZAG to attenuate type 2 diabetes in the ob/ob mouse model. ZAG (50 microg daily, iv) induced a progressive loss of body weight (3.5 g in 5 d), without an effect on food or water intake but with a 0.4 C rise in body temperature, suggesting an increased energy expenditure. Despite an increased plasma glycerol, indicative of increased lipolysis, levels of glucose, triglycerides, and nonesterified fatty acids were decreased by 17, 25, and 62%, respectively, due to an increased use of both glucose and lipids by muscle and brown adipose tissue. The weight of the latter increased 2-fold, and there was increased expression of uncoupling proteins-1 and -3. Plasma insulin levels were reduced by 36%, whereas pancreatic insulin was increased 4-fold, and there was a 53% decrease in the total area under the glucose curve in the glucose tolerance test and reduced insulin requirement. There was an increase in skeletal muscle mass due to an increase in protein synthesis and a decrease in protein degradation. These results suggest that ZAG may potentially be effective in the treatment of type 2 diabetes.
LanguageEnglish
Pages948-957
Number of pages10
JournalEndocrinology
Volume151
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

Hypoglycemic Agents
Zinc
Glycoproteins
Insulin
Glucose
Type 2 Diabetes Mellitus
Cachexia
Adipokines
Brown Adipose Tissue
Lipolysis
Glucose Tolerance Test
Body Temperature
Nonesterified Fatty Acids
Glycerol
Energy Metabolism
Proteolysis
Drinking
Area Under Curve
Skeletal Muscle
Triglycerides

Bibliographical note

Copyright © 2010 by The Endocrine Society

Keywords

  • type II
  • type 2
  • diabetes
  • zinc-alpha2-glycoprotein

Cite this

Russell, Steve T. ; Tisdale, Michael J. / Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. In: Endocrinology. 2010 ; Vol. 151, No. 3. pp. 948-957.
@article{82b3d3388e824a7ba23c07379fa430b0,
title = "Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice",
abstract = "Zinc-alpha(2)-glycoprotein (ZAG) is an adipokine associated with fat loss in cancer cachexia. The purpose of this study was to evaluate the ability of recombinant human ZAG to attenuate type 2 diabetes in the ob/ob mouse model. ZAG (50 microg daily, iv) induced a progressive loss of body weight (3.5 g in 5 d), without an effect on food or water intake but with a 0.4 C rise in body temperature, suggesting an increased energy expenditure. Despite an increased plasma glycerol, indicative of increased lipolysis, levels of glucose, triglycerides, and nonesterified fatty acids were decreased by 17, 25, and 62{\%}, respectively, due to an increased use of both glucose and lipids by muscle and brown adipose tissue. The weight of the latter increased 2-fold, and there was increased expression of uncoupling proteins-1 and -3. Plasma insulin levels were reduced by 36{\%}, whereas pancreatic insulin was increased 4-fold, and there was a 53{\%} decrease in the total area under the glucose curve in the glucose tolerance test and reduced insulin requirement. There was an increase in skeletal muscle mass due to an increase in protein synthesis and a decrease in protein degradation. These results suggest that ZAG may potentially be effective in the treatment of type 2 diabetes.",
keywords = "type II, type 2, diabetes, zinc-alpha2-glycoprotein",
author = "Russell, {Steve T.} and Tisdale, {Michael J.}",
note = "Copyright {\circledC} 2010 by The Endocrine Society",
year = "2010",
month = "3",
doi = "10.1210/en.2009-0827",
language = "English",
volume = "151",
pages = "948--957",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice. / Russell, Steve T.; Tisdale, Michael J.

In: Endocrinology, Vol. 151, No. 3, 03.2010, p. 948-957.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antidiabetic properties of zinc-alpha2-glycoprotein in ob/ob mice

AU - Russell, Steve T.

AU - Tisdale, Michael J.

N1 - Copyright © 2010 by The Endocrine Society

PY - 2010/3

Y1 - 2010/3

N2 - Zinc-alpha(2)-glycoprotein (ZAG) is an adipokine associated with fat loss in cancer cachexia. The purpose of this study was to evaluate the ability of recombinant human ZAG to attenuate type 2 diabetes in the ob/ob mouse model. ZAG (50 microg daily, iv) induced a progressive loss of body weight (3.5 g in 5 d), without an effect on food or water intake but with a 0.4 C rise in body temperature, suggesting an increased energy expenditure. Despite an increased plasma glycerol, indicative of increased lipolysis, levels of glucose, triglycerides, and nonesterified fatty acids were decreased by 17, 25, and 62%, respectively, due to an increased use of both glucose and lipids by muscle and brown adipose tissue. The weight of the latter increased 2-fold, and there was increased expression of uncoupling proteins-1 and -3. Plasma insulin levels were reduced by 36%, whereas pancreatic insulin was increased 4-fold, and there was a 53% decrease in the total area under the glucose curve in the glucose tolerance test and reduced insulin requirement. There was an increase in skeletal muscle mass due to an increase in protein synthesis and a decrease in protein degradation. These results suggest that ZAG may potentially be effective in the treatment of type 2 diabetes.

AB - Zinc-alpha(2)-glycoprotein (ZAG) is an adipokine associated with fat loss in cancer cachexia. The purpose of this study was to evaluate the ability of recombinant human ZAG to attenuate type 2 diabetes in the ob/ob mouse model. ZAG (50 microg daily, iv) induced a progressive loss of body weight (3.5 g in 5 d), without an effect on food or water intake but with a 0.4 C rise in body temperature, suggesting an increased energy expenditure. Despite an increased plasma glycerol, indicative of increased lipolysis, levels of glucose, triglycerides, and nonesterified fatty acids were decreased by 17, 25, and 62%, respectively, due to an increased use of both glucose and lipids by muscle and brown adipose tissue. The weight of the latter increased 2-fold, and there was increased expression of uncoupling proteins-1 and -3. Plasma insulin levels were reduced by 36%, whereas pancreatic insulin was increased 4-fold, and there was a 53% decrease in the total area under the glucose curve in the glucose tolerance test and reduced insulin requirement. There was an increase in skeletal muscle mass due to an increase in protein synthesis and a decrease in protein degradation. These results suggest that ZAG may potentially be effective in the treatment of type 2 diabetes.

KW - type II

KW - type 2

KW - diabetes

KW - zinc-alpha2-glycoprotein

UR - http://www.scopus.com/inward/record.url?scp=77149178714&partnerID=8YFLogxK

UR - http://endo.endojournals.org/cgi/content/abstract/151/3/948?maxtoshow=&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=phrase&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

U2 - 10.1210/en.2009-0827

DO - 10.1210/en.2009-0827

M3 - Article

VL - 151

SP - 948

EP - 957

JO - Endocrinology

T2 - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -